Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsSeeking Alpha • 04/05/24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumorsGlobeNewsWire • 04/02/24
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass EstimatesZacks Investment Research • 03/25/24
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 03/25/24
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 03/21/24
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?Zacks Investment Research • 02/28/24
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCGlobeNewsWire • 01/04/24
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024GlobeNewsWire • 12/14/23
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023GlobeNewsWire • 12/11/23
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology SummitGlobeNewsWire • 12/04/23
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 11/13/23
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023GlobeNewsWire • 10/22/23
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC ConferenceGlobeNewsWire • 10/16/23
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated MilestonesGlobeNewsWire • 08/10/23
All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to BuyZacks Investment Research • 07/12/23